Issue Archive
October 2019 | Volume 18 | Issue 10
Editorials
Treatment of Recalcitrant Acrodermatitis Continua of Hallopeau With Brodalumab
Acrodermatitis continua of Hallopeau (ACH) is a relatively rare chronic disorder with clinical findings of pustules and erythematous plaques on the digits.1 Although it is a variant of pustular psoria...
Read MoreNon-Melanoma Skin Cancer Risk Among Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
Patients with psoriasis are at increased risk of developing non melanoma skin cancer (NMSC), including squamous cell carcinoma (SCC) and basal cell carcinoma (BCC).1,2 The risk is especially elevated ...
Read MorePyogenic Granuloma of the Lip With Complete Resolution After Topical Propranolol
An otherwise-healthy 27-year-old male patient presented with a 3-month history of an asymptomatic, non-bleeding, rapidly growing nodule, on his left upper vermilion lip....
Read More
Original Articles
Impact of Gene Expression Profile Testing on the Management of Squamous Cell Carcinoma by Dermatologists
Background: The incidence of cutaneous squamous cell carcinoma (cSCC) is increasing likely due to improved detection and a growing elderly population. Although the prognosis of cSCC is excellent with ...
Read MorePrescribing Patterns for Atopic Dermatitis in the United States
Introduction: Although future atopic dermatitis (AD) clinical research is intended to improve standard-of-care treatment, how patients are currently treated is not well characterized. The purpose of t...
Read MoreCharacterizing Pruritus in Autoimmune Connective Tissue Diseases
Background: Autoimmune connective tissue diseases (ACTDs) are a broad range of diseases featured by immune dysregulation, and often have multisystem involvement with prominent skin manifestations. Pru...
Read MoreThe Low Prevalence of Allergic Contact Dermatitis Using a Petrolatum Ointment Containing Lanolin Alcohol
Lanolin alcohol is a high cholesterol containing naturally derived material used as a skin protectant in wound healing petrolatum-based ointments. It is a highly purified fraction of lanolin wool wax ...
Read MoreBeta-Blockers for Pyogenic Granuloma: A Systematic Review of Case Reports, Case Series, and Clinical Trials
Pyogenic granuloma (PG) is an acquired vascular growth on the skin and mucous membranes. Even though PG is a benign tumor, treatment is required due to associated risk of ulceration and bleeding, cosm...
Read MoreEfficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials
Background: The use of topical therapy is a key component in the management of almost all psoriasis patients. Topicals are considered first-line therapy for mild disease and are having an increasing r...
Read MoreA Global Review on the Risk Factors and Management of Early Atopic Dermatitis in Children Ages 0 to 2 Years Old
Introduction: Atopic dermatitis (AD) is a chronic, relapsing skin disease starting typically in atopic-prone children between 3–6 months of age, with most children having developed atopic dermat...
Read MoreHalobetasol 0.01% Lotion in the Treatment of Moderate- to-Severe Plaque Psoriasis of the Lower Extremities
Background: Psoriasis is a chronic, immune-mediated disease that varies widely in its clinical expression. Topical corticosteroids (TCS) are the mainstay of treatment. Long-term safety remains a conce...
Read MoreEfficacy of Topical Botanical Treatment of Children With Mild to Moderate Atopic Dermatitis
Objective: The study was conducted to determine the efficacy of the botanical combination incorporated in Kamedis Eczema Therapy Cream (the test product) for children with mild to moderate atopic derm...
Read More
Features
Recommendations for Prevention of Drug Re-Exposure in Toxic Epidermal Necrolysis
Drug re-exposure resulting in Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) is a rare phenomenon and has scarcely been reported. With an aging population, polypharmacy, and a lack...
Read MoreDupilumab in Dermatology: Potential for Uses Beyond Atopic Dermatitis
Dupilumab inhibits the interleukin-4 receptor subunit α and is FDA approved for treatment of moderate-to-severe atopic dermatitis. It is a relatively new drug, and whether it is efficacious for ...
Read MorePIPELINE PREVIEWS
Upcoming news...
Read More
